Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes
September 13, 2022 08:02 ET
|
Novome Biotechnologies, Inc.
- Funding supports ongoing Phase 2a clinical trial in patients with enteric hyperoxaluria, and pipeline of GEMMs candidates for inflammatory bowel disease - - Financing includes new investors led by...
Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001
November 17, 2021 09:02 ET
|
Novome Biotechnologies, Inc.
- Orally-administered Genetically Engineered Microbial Medicine (GEMM) was safe and well tolerated and demonstrated dose-dependent strain engraftment in healthy volunteers - - Results provide...
Novome Biotechnologies and Genentech Enter into a Strategic Collaboration to Develop Targets Against Inflammatory Bowel Disease
November 10, 2021 08:32 ET
|
Novome Biotechnologies, Inc.
- Collaboration will leverage Novome’s GEMMs platform for colonizing the human gut with therapeutically engineered bacteria - - Novome to receive $15 million upfront payment; potential to receive up...
Novome Biotechnologies Appoints Bill McLeod as Chief Financial Officer
October 20, 2021 09:02 ET
|
Novome Biotechnologies, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, today...
Novome Biotechnologies Initiates Phase 1/2a Study to Evaluate Therapeutically Engineered Bacteria for the Treatment of Enteric Hyperoxaluria
June 30, 2021 09:00 ET
|
Novome Biotechnologies, Inc.
- NOV-001 is the first therapeutically engineered colonizing gut bacteria to be evaluated in humans - - Phase 1 results anticipated in 2021 and Phase 2a preliminary efficacy results in 2022 - SOUTH...
Novome Biotechnologies Appoints Dr. Lachy McLean as Chief Medical Officer
June 22, 2021 08:00 ET
|
Novome Biotechnologies, Inc.
SOUTH SAN FRANCISCO, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today...